New Diagnostic and Molecular Characteristics of Malignant Mesothelioma

Malignant mesothelioma is a primary cancer of the serosal cavities, an anatomic site that is also frequently affected by metastatic disease, predominantly from primary carcinomas of the lung, breast, and ovary. Advances in immunohistochemistry have resulted in improved diagnostic sensitivity and specificity in the differential diagnosis between metastatic adenocarcinoma and malignant mesothelioma in both cytological and histological material. Recently, the author's group applied high throughput technology to the identification of new markers that may aid in differentiating malignant mesothelioma from ovarian and peritoneal serous carcinoma, tumors with closely related histogenesis and antigenic profile. In addition to the improved tools available for serosal cancer diagnosis, knowledge regarding the biology of malignant mesothelioma has been accumulating in recent years. This review presents current data regarding the diagnostic and biological aspects of malignant mesothelioma.

[1]  R. Salgia,et al.  MET as a target for treatment of chest tumors. , 2009, Lung cancer.

[2]  P. Nikolinakos,et al.  The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell Lung Cancer and Other Thoracic Malignancies , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  G. Gordon,et al.  mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. , 2008, American journal of respiratory cell and molecular biology.

[4]  Ben Davidson,et al.  Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. , 2008, Human pathology.

[5]  H. Sasaki,et al.  Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma , 2008, Journal of Cancer Research and Clinical Oncology.

[6]  G. Gordon,et al.  Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma , 2008, Cancer Chemotherapy and Pharmacology.

[7]  N. Probst-Hensch,et al.  PTEN expression is a strong predictor of survival in mesothelioma patients. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  H. Pass,et al.  HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. , 2008, American journal of respiratory cell and molecular biology.

[9]  F. Galateau-Sallé,et al.  EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors , 2007, Thorax.

[10]  I. Shih,et al.  MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells , 2007, Diagnostic cytopathology.

[11]  B. Davidson.  Biological characteristics of cancers involving the serosal cavities. , 2007, Critical reviews in oncogenesis.

[12]  M. Daidone,et al.  Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[13]  C. Porta,et al.  Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma , 2007, Clinical Cancer Research.

[14]  I. Shih,et al.  Low‐molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma , 2007, Cancer.

[15]  J. Nesland,et al.  Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. , 2007, American journal of clinical pathology.

[16]  H. Mackay,et al.  Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185 , 2007, Current oncology.

[17]  Mitchell Ho,et al.  A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses , 2007, Clinical Cancer Research.

[18]  J. Nesland,et al.  Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. , 2007, Human pathology.

[19]  I. Shih,et al.  Amplicon profiles in ovarian serous carcinomas , 2007, International journal of cancer.

[20]  A. Klein-Szanto,et al.  Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  I. Shih,et al.  The diagnostic role of claudins in serous effusions. , 2007, American journal of clinical pathology.

[22]  A. Berner,et al.  Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. , 2007, American journal of clinical pathology.

[23]  I. V. van Driel,et al.  Infiltration of a Mesothelioma by IFN-γ-Producing Cells and Tumor Rejection after Depletion of Regulatory T Cells1 , 2007, The Journal of Immunology.

[24]  G. Gordon,et al.  Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma , 2007, The Journal of pathology.

[25]  S. Batra,et al.  MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. , 2007, Lung cancer.

[26]  J. Nesland,et al.  Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma , 2007, Cancer.

[27]  S. Batra,et al.  Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. , 2007, Cancer research.

[28]  B. Davidson,et al.  Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. , 2006, Lung cancer.

[29]  A. Berner,et al.  Cadherin Expression in Ovarian Carcinoma and Malignant Mesothelioma Cell Effusions , 2006, Acta Cytologica.

[30]  Lynette M. Smith,et al.  Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) , 2006, Modern Pathology.

[31]  I. Shih,et al.  Gene Expression Signatures Differentiate Ovarian/Peritoneal Serous Carcinoma from Diffuse Malignant Peritoneal Mesothelioma , 2006, Clinical Cancer Research.

[32]  S. Baker,et al.  PTEN function in normal and neoplastic growth. , 2006, Cancer letters.

[33]  S. Batra,et al.  MUC4 Is a Novel Prognostic Factor of Extrahepatic Bile Duct Carcinoma , 2006, Clinical Cancer Research.

[34]  Kyle J Hewitt,et al.  The claudin gene family: expression in normal and neoplastic tissues , 2006, BMC Cancer.

[35]  R. Stahel,et al.  p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. , 2006, Neoplasia.

[36]  J. Nesland,et al.  D2-40 is Not a Specific Marker for Cells of Mesothelial Origin in Serous Effusions , 2006, The American journal of surgical pathology.

[37]  A. Borczuk,et al.  Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  H. Hammad,et al.  Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses , 2006, European Respiratory Journal.

[39]  J. Creaney,et al.  Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. , 2006, Lung cancer.

[40]  I. Shih,et al.  Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma , 2006, Virchows Archiv.

[41]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[42]  Y. Soini,et al.  Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura , 2006, Journal of Clinical Pathology.

[43]  C. V. Van Itallie,et al.  Claudins and epithelial paracellular transport. , 2006, Annual review of physiology.

[44]  G. Ceresoli,et al.  EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. , 2006, Lung cancer.

[45]  M. Lind,et al.  Expression of Bcl-2 Family Members in Malignant Pleural Mesothelioma , 2006, Acta oncologica.

[46]  N. Ordóñez.  Value of Immunohistochemistry in Distinguishing Peritoneal Mesothelioma From Serous Carcinoma of the Ovary and Peritoneum: A Review and Update , 2006, Advances in anatomic pathology.

[47]  Antonio Di Cristofano,et al.  Class reunion: PTEN joins the nuclear crew , 2005, Oncogene.

[48]  P. Morin,et al.  Claudin proteins in human cancer: promising new targets for diagnosis and therapy. , 2005, Cancer research.

[49]  S. Emri,et al.  Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma. , 2005, Lung cancer.

[50]  H. P. Dong,et al.  Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping , 2005, Diagnostic cytopathology.

[51]  J. Nesland,et al.  Angiogenic Molecule Expression is Downregulated in Effusions from Breast Cancer Patients , 2005, Breast Cancer Research and Treatment.

[52]  A. Yılmaz,et al.  Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. , 2005, Chest.

[53]  A. Berner,et al.  Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities , 2005, Diagnostic cytopathology.

[54]  James M. Wilson,et al.  Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy , 2005, Clinical Cancer Research.

[55]  I. Ellis,et al.  Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer , 2005, Modern Pathology.

[56]  P. Morin,et al.  Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. , 2005, Cancer research.

[57]  S. Batra,et al.  MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas , 2005, Journal of Clinical Pathology.

[58]  C. Obasaju,et al.  Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. , 2005, Clinical lung cancer.

[59]  P. Fouret,et al.  MUC1, MUC2, MUC4, and MUC5AC Expression in Salivary Gland Mucoepidermoid Carcinoma: Diagnostic and Prognostic Implications , 2005, The American journal of surgical pathology.

[60]  A. Berner,et al.  Mitogen‐activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells , 2005, Cancer.

[61]  A. Marchetti,et al.  Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. , 2005, Lung cancer.

[62]  P. Clement,et al.  Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. , 2005, American journal of clinical pathology.

[63]  P. Clement,et al.  Malignant Peritoneal Mesothelioma in Women , 2005 .

[64]  M. Kubbies,et al.  Role of claudins in tumorigenesis. , 2005, Advanced drug delivery reviews.

[65]  B. Clurman,et al.  Cyclin E in normal and neoplastic cell cycles , 2005, Oncogene.

[66]  P. Hinds,et al.  Cyclins and cdks in development and cancer: a perspective , 2005, Oncogene.

[67]  P. Sugarbaker,et al.  Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy , 2005, Cancer.

[68]  R. Ozols.  Treatment goals in ovarian cancer , 2005, International Journal of Gynecologic Cancer.

[69]  Chuong D. Hoang,et al.  Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells , 2004, Cancer Research.

[70]  L. Kaiser,et al.  Soluble Type II Transforming Growth Factor-β Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity , 2004, Clinical Cancer Research.

[71]  Biao He,et al.  Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma , 2004, Oncogene.

[72]  T. Peretz,et al.  Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. , 2004, Journal of the National Cancer Institute.

[73]  Yaqoub Ashhab,et al.  The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. , 2004, Seminars in cancer biology.

[74]  R. Damhuis,et al.  Prognostic factors in malignant mesothelioma. , 2004, Lung cancer.

[75]  R. Drapkin,et al.  Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. , 2004, Human pathology.

[76]  D. Fennell,et al.  Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. , 2004, The Lancet. Oncology.

[77]  B. Davidson,et al.  Laminin-Induced Signaling in Tumor Cells , 2004, Cancer Research.

[78]  Amie Y Lee,et al.  Inhibition of Wnt-1 Signaling Induces Apoptosis in β-Catenin-Deficient Mesothelioma Cells , 2004, Cancer Research.

[79]  G. Vicidomini,et al.  Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma , 2004, Thorax.

[80]  V. A. Flørenes,et al.  Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. , 2004, Lung cancer.

[81]  S. Toyooka,et al.  Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types , 2004, International journal of cancer.

[82]  I. Bedrosian,et al.  Cyclin E deregulation alters the biologic properties of ovarian cancer cells , 2004, Oncogene.

[83]  Federico Garrido,et al.  The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape , 2004, Cancer Immunology, Immunotherapy.

[84]  K. O'Byrne,et al.  Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[85]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[86]  Seth M Steinberg,et al.  Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  J. Collins,et al.  Cadherins, catenins and APC in pleural malignant mesothelioma , 2003, The Journal of pathology.

[88]  C. Parker,et al.  Lung cancer • 8: Management of malignant mesothelioma , 2003, Thorax.

[89]  N. Ordóñez.  Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma. , 2003, Human pathology.

[90]  B. Mossman,et al.  Cell signaling and transcription factor activation by asbestos in lung injury and disease. , 2003, The international journal of biochemistry & cell biology.

[91]  Olivier De Wever,et al.  Role of tissue stroma in cancer cell invasion , 2003, The Journal of pathology.

[92]  P. Casali,et al.  Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion , 2003, Journal of surgical oncology.

[93]  P. Sugarbaker,et al.  A review of peritoneal mesothelioma at the Washington Cancer Institute. , 2003, Surgical oncology clinics of North America.

[94]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[95]  M. Ladanyi,et al.  Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[96]  K. O'Byrne,et al.  Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura , 2003, British Journal of Cancer.

[97]  P. Argani,et al.  Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast , 2003, Oncogene.

[98]  A. Hjerpe,et al.  Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium , 2003, The Journal of pathology.

[99]  L. Morrison,et al.  Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. , 2003, Cancer research.

[100]  Z. Liu,et al.  Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors , 2003, Thorax.

[101]  Paul Baas,et al.  Surgical treatment of malignant pleural mesothelioma: a review. , 2003, Chest.

[102]  Isabelle Bedrosian,et al.  Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.

[103]  B. Mossman,et al.  Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. , 2002, Cancer research.

[104]  D. Taatjes,et al.  A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression. , 2002, Cancer research.

[105]  U. Brinck,et al.  The Potential Value of Comparative Genomic Hybridization Analysis in Effusion—and Fine Needle Aspiration Cytology , 2002, Modern Pathology.

[106]  K. Uematsu,et al.  Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. , 2002, Molecular cancer therapeutics.

[107]  A. Berner,et al.  Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. , 2002, American journal of clinical pathology.

[108]  G. Gordon,et al.  Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. , 2002, Carcinogenesis.

[109]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[110]  S. Martinotti,et al.  Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen , 2002, Oncogene.

[111]  F. Balkwill,et al.  The role of cytokines in the epithelial cancer microenvironment. , 2002, Seminars in cancer biology.

[112]  A. Zlotnik,et al.  Chemokines: agents for the immunotherapy of cancer? , 2002, Nature Reviews Immunology.

[113]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[114]  M. Hanada,et al.  [Regulation of stress-activated protein kinase signaling pathways by protein phosphatases]. , 2002, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[115]  B. Hemmings,et al.  Inhibition of protein kinase B/Akt. implications for cancer therapy. , 2002, Pharmacology & therapeutics.

[116]  P. Clement,et al.  Diffuse malignant epithelial mesotheliomas of the peritoneum in women , 2002, Cancer.

[117]  A. Berner,et al.  The Role of Desmin and N-Cadherin in Effusion Cytology: A Comparative Study Using Established Markers of Mesothelial and Epithelial Cells , 2001, The American journal of surgical pathology.

[118]  K. Geisinger,et al.  Prospective Trial for the Treatment of Malignant Peritoneal Mesothelioma , 2001, The American surgeon.

[119]  P. Cassoni,et al.  p27kip1 immunoreactivity correlates with long‐term survival in pleural malignant mesothelioma , 2001, Cancer.

[120]  K. O'Byrne,et al.  Angiogenesis is an independent prognostic factor in malignant mesothelioma , 2001, British Journal of Cancer.

[121]  Mollianne J. McGahren,et al.  Tumor-Specific Proteolytic Processing of Cyclin E Generates Hyperactive Lower-Molecular-Weight Forms , 2001, Molecular and Cellular Biology.

[122]  James M. Wilson,et al.  Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. , 2001, Cancer research.

[123]  A. Jochemsen,et al.  WT1 proteins: functions in growth and differentiation. , 2001, Gene.

[124]  M. Metintaş,et al.  p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. , 2001, Respiratory medicine.

[125]  P. Shepherd,et al.  p27 immunostaining is related to prognosis in malignant mesothelioma , 2001, Histopathology.

[126]  L. Strizzi,et al.  Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. , 2001, International journal of oncology.

[127]  Shoichiro Tsukita,et al.  Multifunctional strands in tight junctions , 2001, Nature Reviews Molecular Cell Biology.

[128]  A. Casalini,et al.  Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma , 2001, The Journal of pathology.

[129]  R. Weinberg,et al.  Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. , 2001, Experimental cell research.

[130]  A. Ivanoff,et al.  Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines , 2001, International journal of cancer.

[131]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[132]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[133]  M. Jaurand,et al.  Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases , 2000, British Journal of Cancer.

[134]  Y. Soini,et al.  Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma , 2000, International journal of cancer.

[135]  M. Moroni,et al.  Interleukin‐2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro , 2000, Journal of cellular physiology.

[136]  F. Escande,et al.  Alternative splicing generates a family of putative secreted and membrane-associated MUC4 mucins. , 2000, European journal of biochemistry.

[137]  J. Nesland,et al.  Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings , 2000, Journal of clinical pathology.

[138]  N. Carr,et al.  Mitotic and in situ end-labeling apoptotic indices as prognostic markers in malignant mesothelioma. , 2000, Annals of diagnostic pathology.

[139]  P. Hasleton,et al.  Immunoreactivity for cadherins, HGF/SF, met, and erbB‐2 in pleural malignant mesotheliomas , 2000, Histopathology.

[140]  S. Dedhar.  Cell-substrate interactions and signaling through ILK. , 2000, Current opinion in cell biology.

[141]  E. Brambilla,et al.  NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas. , 2000, Human pathology.

[142]  K. Müller,et al.  Co-Expression of Vascular Endothelial Growth Factor and Its Receptor flt-1 in Malignant Pleural Mesothelioma , 2000, Respiration.

[143]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[144]  M. Camps,et al.  Dual specificity phosphatases: a gene family for control of MAP kinase function , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[145]  Y. Soini,et al.  Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[146]  E. van Marck,et al.  Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression , 1999, The Journal of pathology.

[147]  R. K. Bright,et al.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours , 1999, British Journal of Cancer.

[148]  S. Libutti,et al.  Treatment of Primary Peritoneal Mesothelioma by Continuous Hyperthermic Peritoneal Perfusion (CHPP) , 1999, Annals of Surgical Oncology.

[149]  K. Müller,et al.  Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma , 1999, Virchows Archiv.

[150]  Fan Gr.  Regulation of the MAPK family members: role of subcellular localization and architectural organization. , 1999 .

[151]  R. K. Bright,et al.  Thrombospondin‐1 expression and clinical implications in malignant pleural mesothelioma , 1999, Cancer.

[152]  G L Johnson,et al.  Organization and regulation of mitogen-activated protein kinase signaling pathways. , 1999, Current opinion in cell biology.

[153]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[154]  N. Moniaux,et al.  Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. , 1999, The Biochemical journal.

[155]  K. Fujimoto,et al.  Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[156]  M. Ward,et al.  Interleukin 8: an autocrine growth factor for malignant mesothelioma. , 1999, Cancer research.

[157]  M. Piver,et al.  Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma , 1999, Journal of surgical oncology.

[158]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[159]  John Calvin Reed,et al.  Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.

[160]  E. Venetsanakos,et al.  Interleukin-12 induces an effective antitumor response in malignant mesothelioma. , 1998, American journal of respiratory cell and molecular biology.

[161]  B. Weyn,et al.  Syndecan‐1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome , 1998, The Journal of pathology.

[162]  K. Müller,et al.  Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma , 1998, Journal of Cancer Research and Clinical Oncology.

[163]  H. Takita,et al.  Malignant pleural mesothelioma: a problematic review. , 1998, Surgical oncology.

[164]  B. Baskin,et al.  Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c‐met receptor , 1998, International journal of cancer.

[165]  R L Juliano,et al.  Integrin signaling and cell growth control. , 1998, Current opinion in cell biology.

[166]  D. Taatjes,et al.  Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. , 1998, The American journal of pathology.

[167]  A. Bellacosa,et al.  Analysis of cyclin E and CDK2 in ovarian cancer: Gene amplification and RNA overexpression , 1998, International journal of cancer.

[168]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[169]  J. Klominek,et al.  Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: The role of β1 integrins , 1997, International journal of cancer.

[170]  K. Johnson,et al.  Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. , 1997, Human pathology.

[171]  E. van Marck,et al.  WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TO p53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELL‐TYPE TRANSITION, AND PROGNOSIS , 1997, The Journal of pathology.

[172]  B. Mossman,et al.  Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. , 1996, Cancer research.

[173]  D T Denhardt,et al.  Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. , 1996, The Biochemical journal.

[174]  R. Zeillinger,et al.  Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors , 1996, International journal of cancer.

[175]  T. H. van der Kwast,et al.  EXPRESSION OF PLATELET‐DERIVED GROWTH FACTOR (PDGF) AND PDGF RECEPTORS IN HUMAN MALIGNANT MESOTHELIOMA IN VITRO AND IN VIVO , 1996, The Journal of pathology.

[176]  F. Nardi,et al.  Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions. , 1995, Acta cytologica.

[177]  S. Selvaggi,et al.  Malignant effusions : a multimodal approach to cytologic diagnosis , 1995 .

[178]  D. Fitzpatrick,et al.  Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model , 1994, Cancer Immunology, Immunotherapy.

[179]  R. Davis,et al.  MAPKs: new JNK expands the group. , 1994, Trends in biochemical sciences.

[180]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[181]  M. Takeichi,et al.  Cadherin cell adhesion receptors as a morphogenetic regulator. , 1991, Science.

[182]  M. Gross,et al.  Molecular cloning and chromosomal localization of a novel human tracheo-bronchial mucin cDNA containing tandemly repeated sequences of 48 base pairs. , 1991, Biochemical and biophysical research communications.

[183]  B. Robinson,et al.  Asbestos fibres inhibit the in vitro activity of ymphokine‐activated killer (LAK) cells from healthy individualsand patients with malignant mesothelioma , 1991, Clinical and experimental immunology.

[184]  P. Hasleton,et al.  Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. , 1990, British Journal of Cancer.

[185]  M. Tucker,et al.  Survival patterns for malignant mesothelioma: The seer experience , 1988, International journal of cancer.

[186]  D. Henson,et al.  Malignant mesothelioma following radiation exposure. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[187]  K. Browne,et al.  The epidemiology of mesothelioma. , 1983, The Journal of the Society of Occupational Medicine.

[188]  A. Moossa,et al.  Peritoneal malignant mesothelioma in a patient with recurrent peritonitis , 1981, Cancer.

[189]  R. Maurer,et al.  Malignant peritoneal mesothelioma after cholangiography with thorotrast , 1975, Cancer.

[190]  K. Carraway,et al.  Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. , 2007, Current topics in developmental biology.

[191]  N. Ordóñez.  What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. , 2007, Human pathology.

[192]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[193]  D. Fennell,et al.  Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). , 2006, Lung cancer.

[194]  P Maisonneuve,et al.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[195]  D. Fennell,et al.  Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM) , 2006 .

[196]  M. Waldstrøm,et al.  Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. , 2005, Archives of pathology & laboratory medicine.

[197]  R. Bresalier,et al.  Mucins and mucin binding proteins in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[198]  E. Mark,et al.  Transforming growth factor α and epidermal growth factor receptor in reactive and malignant mesothelial proliferations , 2004 .

[199]  A. Berner,et al.  Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma , 2004, Clinical & Experimental Metastasis.

[200]  J. Nesland,et al.  Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions , 2004, Clinical & Experimental Metastasis.

[201]  P. Nava,et al.  Tight junction proteins. , 2003, Progress in biophysics and molecular biology.

[202]  J. Slingerland,et al.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.

[203]  G. Fanger,et al.  Regulation of the MAPK family members : Role of subcellular localization and architectural organization , 2011 .

[204]  B. Baskin,et al.  Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. , 1998, Clinical & experimental metastasis.

[205]  W. Warren,et al.  Pleural mesotheliomas have an integrin profile distinct from visceral carcinomas. , 1997, Human pathology.

[206]  S. Rosenberg,et al.  implications for cancer therapy , 1996 .

[207]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[208]  Ramon Silva Martins,et al.  Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[209]  C A SALVATORE,et al.  [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.